Global Genomic Biomarker Market Research and Forecast 2018-2023

  • ID: 4602814
  • Report
  • Region: Global
  • Orion Market Research Private Limited
15 % OFF
until Dec 31st 2018
1 of 4


  • 23Andme
  • Contextual Genomics Inc.
  • Epigenomics Ag
  • Hologic, Inc.
  • Luminex Corporation
  • Pfizer Inc.
  • MORE
Genomics is a field of science that is mainly focused on the structure, evolution, function and mapping of genomes. Genomics aims for the collective characterization and quantification of genes. Genomics additionally includes the sequencing and analysis of genomes using high-throughput DNA sequencing and bioinformatics for assembling and analysing the function and structure of entire genomes. The field also includes studies of intragenomic (within the genome) phenomena such as epistasis (effect of one gene on another), pleiotropy (one gene affecting more than one trait), heterosis (hybrid vigour), and other interactions between loci and alleles within the genome. Genomic data about any disease is improving detection and treatment techniques for various diseases. Biomarkers are biological measurements that can be used for a variety of purposes such as identifying individuals who are at high risk of developing a disease, when it is treatable, and diagnostic classi?cation for personalized treatment on the basis of biological characterization of the disease of each individual patient.

Major factors contributing to the growth of the global genomic biomarker market include increasing prevalence of chronic diseases such as cancer, cardiovascular diseases, neurological disorders and others. Other driving factors include increasing research and investment in the field of genomic biomarkers and use of genomic biomarker services for the enhancement of drug development pipelines. For example: Discovery and Development Solutions business of the Millipore, a division of the Merck KGaA, Germany announced that it will be offering genomic biomarker services for supporting drug companies in targeting patient sub-groups for enhanced clinical outcomes, understanding of drug safety and efficacy, and characterization of tumors.

The genomic biomarker market can be segmented according to disease indication and end users. As per disease indications, the market is further bifurcated as oncology, cardiology, neurology and others such as nephrology. On the basis of end users, the genomic biomarker market is diversified as hospitals; and diagnostic and research laboratories. The genomic biomarker market on the basis of disease indication is dominated by oncology segment and it is expected that the segment will remain dominant in the coming years. This is due to increasing cancer prevalence. In addition, there is a wide adoption of genomic biomarker for screening or diagnostic and prognostic tests of the cancer. For example: Cancer Discovery Initiative taken by Illumina is focused on identifying genomic and transcriptomics biomarkers for ovarian, gastric, and colorectal cancers.

The global genomic biomarker market is further analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. The North America is expected to dominate the global genomic biomarker market owing to large number of clinical research activities for genomic biomarker in this region. Europe is another significant market and holds a considerable market share in the global genomic biomarker market.

Some of the key players operating in the global genomic biomarker market are Bio-Rad Laboratories, Beckman Coulter Inc., Myriad Genetics, Inc., Thermo Fisher Scientific, Roche Diagnostics and several others. In order to sustain in the competitive market, these players adopt various strategies such as merger & acquisitions, expansions, joint ventures and product development and partnership and collaboration. For instance, Illumina Inc., in April 2018 has entered into a partnership with Bristol-Myers Squibb Company. With this collaboration, next-generation sequencing (NGS) technology of the Illumina will be utilized for the development and global commercialization of IVD assays in support of oncology portfolio of Bristol-Myers Squibb. The company is focusing on the development of diagnostic version of the Illumina TruSight Oncology 500 assay for measuring potentially predictive genomic biomarkers such as Tumor Mutation Burden (TMB).

Research Methodology

The market study of genomic biomarker market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.

Secondary sources include:

Financial reports of companies involved in the market
Authentic Public Databases such as American College of Rheumatology, American Association for Clinical Chemistry (AACC), and American Autoimmune Related Diseases Association (AARDA), among others.
Whitepapers, research-papers, and news blogs
Company websites and their product catalogue
Supplier Websites such as Alibaba, amazon for pricing analysis

The report is intended for drug manufacturers, healthcare provider, government organizations for overall market analysis, and competitive analysis. The report provides in-depth analysis on pricing, market size, intended quality of the product preferred by consumers, initial norms and vehicle segment. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models such as PEST analysis, Porter five analysis delivering insights into the market for better business decisions.

Market Segmentation:

Global Genomic biomarker market is segmented on the basis of regional outlook and following segments:

Global Genomic biomarker Market Research and Analysis, By Disease Indication
Global Genomic biomarker Market Research and Analysis, By End Users
Global Genomic biomarker Market Research and Analysis, By Region

The Report covers:

Comprehensive research methodology of global genomic biomarker market.
This report also includes detailed and extensive market overview with key analyst insights.
Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global genomic biomarker market.
Insights about market determinants which are stimulating the global genomic biomarker market.
Detailed and extensive market segments with regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown
2 of 4


  • 23Andme
  • Contextual Genomics Inc.
  • Epigenomics Ag
  • Hologic, Inc.
  • Luminex Corporation
  • Pfizer Inc.
  • MORE
Chapter 1. Report Summary
1.1. Research Methods And Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
1.2.3. By Stakeholders

Chapter 2. Market Overview And Insights
2.1. Market Definition
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendation
2.2.3. Conclusion
2.3. Rules & Regulations United States European Union China Japan India

Chapter 3. Market Determinant
3.1. Motivators
3.1.1. Rising Prevalence Of Various Chronic Diseases
3.1.2. Increasing Investment And Research In Genomic Biomarkers
3.1.3. Genomic Biomarker Services For Improving Drug Development Pipelines
3.1.4. Rising Demnad For Minimally Invasive Procedures For Disease Diagnostics
3.2. Restraints
3.2.1. Reimbursement Challenges
3.2.2. Limited Market Capabilities In Underdeveloped Markets
3.3. Opportunities
3.3.1. Genomic Biomarker In Development Of Personalized Medicine
3.3.2. Rising Demand From Emerging Economies

Chapter 4. Market Segmentation
4.1. Global Genomic Biomarker Market, By Disease Indication
4.1.1. Oncology
4.1.2. Cardiology
4.1.3. Neurology
4.1.4. Others
4.2. Global Genomic Biomarker By End Users
4.2.1. Hospitals
4.2.2. Diagnostic And Research Laboratories

Chapter 5. Competitive Landscape
5.1. Key Company Analysis
5.2. Key Strategy Analysis

Chapter 6. Regional Analysis
6.1. North American
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. U.K
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Roe
6.3. Asia Pacific
6.3.1. India
6.3.2. China
6.3.3. Taiwan
6.3.4. Japan
6.3.5. Roapac
6.4. Rest Of The World

Chapter 7. Company Profiles
7.1. 23Andme
7.2. Acobiom Sas
7.3. Agilent Technologies Inc.
7.4. Almac Group
7.5. Bio-Rad Laboratories, Inc.
7.6. Celgene Corporation
7.7. Cofactor Genomics, Inc
7.8. Contextual Genomics Inc.
7.9. Cypher Genomics, Inc.
7.10. Destina Genomics Ltd
7.11. Dnavision Sa
7.12. Eagle Genomics Ltd.
7.13. Empire Genomics, Llc.
7.14. Epigenomics Ag
7.15. Epistem Ltd.
7.16. Eurofins Scientific Se
7.17. Foundation Medicine, Inc.
7.18. Genenews Limited
7.19. Genomic Health, Inc.
7.20. Hologic, Inc.
7.21. Human Longevity, Inc.
7.22. Illumina, Inc
7.23. Insight Genetics Inc.
7.24. Integragen Sa
7.25. Liquid Genomics, Inc.
7.26. Luminex Corporation
7.27. Merck Kgaa,
7.28. Myriad Genetics
7.29. Neogenomics Laboratories, Inc.
7.30. New England Biolabs Inc.
7.31. Oncomed Pharmaceuticals, Inc.
7.32. Origene Technologies, Inc.
7.33. Pamgene International Bv
7.34. Personalis, Inc.
7.35. Pfizer Inc.
7.36. Qiagen N.V.
7.37. Roche Diagnostics
7.38. Thermo Fisher Scientific
7.39. Valirx Plc
7.40. Verge Genomics Inc.
Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • 23Andme
  • Acobiom Sas
  • Agilent Technologies Inc.
  • Almac Group
  • Bio-Rad Laboratories, Inc.
  • Celgene Corporation
  • Cofactor Genomics, Inc
  • Contextual Genomics Inc.
  • Cypher Genomics, Inc.
  • Destina Genomics Ltd
  • Dnavision Sa
  • Eagle Genomics Ltd.
  • Empire Genomics, Llc.
  • Epigenomics Ag
  • Epistem Ltd.
  • Eurofins Scientific Se
  • Foundation Medicine, Inc.
  • Genenews Limited
  • Genomic Health, Inc.
  • Hologic, Inc.
  • Human Longevity, Inc.
  • Illumina, Inc
  • Insight Genetics Inc.
  • Integragen Sa
  • Liquid Genomics, Inc.
  • Luminex Corporation
  • Merck Kgaa,
  • Myriad Genetics
  • Neogenomics Laboratories, Inc.
  • New England Biolabs Inc.
  • Oncomed Pharmaceuticals, Inc.
  • Origene Technologies, Inc.
  • Pamgene International Bv
  • Personalis, Inc.
  • Pfizer Inc.
  • Qiagen N.V.
  • Roche Diagnostics
  • Thermo Fisher Scientific
  • Valirx Plc
  • Verge Genomics Inc.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown